<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00758706</url>
  </required_header>
  <id_info>
    <org_study_id>D4260C00007</org_study_id>
    <nct_id>NCT00758706</nct_id>
  </id_info>
  <brief_title>A Phase IIa Study Assessing the Effects of AZD1236 on Biomarkers in Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
  <acronym>BICO</acronym>
  <official_title>A Double-blind, Randomised, Placebo-controlled, Parallel Group Multi-centre Phase IIa Study to Assess the Effects on Biomarkers in Induced Sputum, Bood and Uine of AZD1236 Administered as Oral Tablet in Moderate to Severe COPD Patients During a 6 Week Period.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to investigate the effects of AZD1236 compared with placebo
      (&quot;inactive substance&quot;) in COPD patients by analysing biomarkers for inflammation and tissue
      degradation in blood, urine and sputum.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of TNF Alpha at Week 6 to Baseline</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Ratio reflects Sputum Tumor Necrosis Factor alpha (TNF alpha) at week 6 value divide by baseline value. Baseline is geometric mean of Visit 2 (last value during run-in) and Visit 3 (Randomization).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of Sputum Total Cells at Week 6 to Baseline</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Ratio reflects Sputum Total Cells at week 6 value divide by baseline value. Baseline is geometric mean of Visit 2 (last value during run-in) and Visit 3 (Randomization).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of Total Urine Desmosine at Week 6 to Baseline</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Ratio reflects Total Urine Desmosine at week 6 value divide by baseline value. Baseline is visit 3(Randomization) value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>all study visits</time_frame>
    <description>Number of patients who had an AE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Expiratory Volume (FEV1) at Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Change from baseline reflects the Week 6 value minus the baseline value. Baseline is visit 3(randomization) value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Vital Capacity (FVC) at Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Change from baseline reflects the Week 6 value minus the baseline value. Baseline is visit 3(randomization) value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital Capacity (VC) at Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Change from baseline reflects the Week 6 value minus the baseline value. Baseline is visit 3(randomization) value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Inspiratory Capacity (IC) at Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Change from baseline reflects the Week 6 value minus the baseline value. Baseline is visit 3(randomization) value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Expiratory Flow (FEF) 25−75% at Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Change from baseline reflects the Week 6 value minus the baseline value. Baseline is visit 3(randomization) value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Peak Expiratory Flow (PEF) Morning at Average of Last 4 Week Treatment</measure>
    <time_frame>Baseline and last 4 week on treatment(Week 1, Week 2, Week 4 and Week 6)</time_frame>
    <description>Change from baseline reflects the average of last 4 week on treatment (Week 1, Week 2, Week 4 and Week 6) minus the baseline value. Baseline is the mean of the last 10 days of data during run-in.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Peak Expiratory Flow (PEF) Evening at Average of Last 4 Week Treatment</measure>
    <time_frame>Baseline and last 4 week on treatment(Week 1, Week 2, Week 4 and Week 6)</time_frame>
    <description>Change from baseline reflects the average of last 4 week on treatment (Week 1, Week 2, Week 4 and Week 6) minus the baseline value. Baseline is the mean of the last 10 days of data during run-in.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical COPD Questionnaire(CCQ) Total</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Change from baseline reflects the Week 6 value minus the baseline value. Baseline is visit 3(randomization) value. The total scores vary between 0 (never/not limited at all) to 6 (almost all the time/totally limited)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in COPD Symptoms, Breathlessness at Average of Last 4 Week Treatment</measure>
    <time_frame>Baseline and last 4 week on treatment(Week 1, Week 2, Week 4 and Week 6)</time_frame>
    <description>Change from baseline reflects the average of last 4 week on treatment (Week 1, Week 2, Week 4 and Week 6) minus the baseline value. Baseline is the mean of the last 10 days of data during run-in. Score vary between 0 (None) to 4 (Severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in COPD Symptoms, Chest Tightness at Average of Last 4 Week Treatment</measure>
    <time_frame>Baseline and last 4 week on treatment(Week 1, Week 2, Week 4 and Week 6)</time_frame>
    <description>Change from baseline reflects the average of last 4 week on treatment (Week 1, Week 2, Week 4 and Week 6) minus the baseline value. Baseline is the mean of the last 10 days of data during run-in. Score vary between 0 (None) to 4 (Severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in COPD Symptoms, Cough Score at Average of Last 4 Week Treatment</measure>
    <time_frame>Baseline and last 4 week on treatment(Week 1, Week 2, Week 4 and Week 6)</time_frame>
    <description>Change from baseline reflects the average of last 4 week on treatment (Week 1, Week 2, Week 4 and Week 6) minus the baseline value. Baseline is the mean of the last 10 days of data during run-in. Score vary between 0 (None) to 4 (Almost Constant).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in COPD Symptoms, Night Time Awakenings at Average of Last 4 Week Treatment</measure>
    <time_frame>Baseline and last 4 week on treatment(Week 1, Week 2, Week 4 and Week 6)</time_frame>
    <description>Change from baseline reflects the average of last 4 week on treatment (Week 1, Week 2, Week 4 and Week 6) minus the baseline value. Baseline is the mean of the last 10 days of data during run-in. Score vary between 0 (None) to 4 (Almost Constant).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>AZD1236</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral tablet, 75 mg, twice daily during 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dosing to match AZD1236</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1236</intervention_name>
    <description>oral tablet, 75 mg, twice daily during 6 weeks</description>
    <arm_group_label>AZD1236</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dosing to match AZD1236</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of COPD for 1 month

          -  Men or postmenopausal women

          -  Spirometry values indicating symptomatic patients

          -  Smoking history equivalent to using 20 cigarettes a day for 10 years.

        Exclusion Criteria:

          -  Any current respiratory tract disorders other than COPD

          -  Requirement for regular oxygen therapy

          -  Acute worsening of COPD (exacerbation) 1,5 month prior to study drug administration

          -  Use of oral or parenteral glucocorticosteroids within 30 days and use of inhaled
             steroids 14 days prior to the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Dahl, MD, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arhus Kommune HospitalMedicinsk</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Lockton, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D Charnwood</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arhus C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kobenhavn Nv</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odense C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Netherlands</country>
    <country>Norway</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=360&amp;filename=CSR-D4260C00007.pdf</url>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=360&amp;filename=CSR-D4260C00007.pdf</url>
    <description>D4260C00007</description>
  </link>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2008</study_first_submitted>
  <study_first_submitted_qc>September 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2008</study_first_posted>
  <results_first_submitted>July 25, 2011</results_first_submitted>
  <results_first_submitted_qc>April 14, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 16, 2015</results_first_posted>
  <last_update_submitted>April 14, 2015</last_update_submitted>
  <last_update_submitted_qc>April 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AZD1236</title>
          <description>AZD1236 75mg oral tablet twice daily(bid)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo to AZD1236 twice daily(bid)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD1236</title>
          <description>AZD1236 75mg oral tablet twice daily(bid)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo to AZD1236 twice daily(bid)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Year</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.9" lower_limit="47" upper_limit="80"/>
                    <measurement group_id="B2" value="65.7" lower_limit="49" upper_limit="79"/>
                    <measurement group_id="B3" value="64.1" lower_limit="47" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ratio of TNF Alpha at Week 6 to Baseline</title>
        <description>Ratio reflects Sputum Tumor Necrosis Factor alpha (TNF alpha) at week 6 value divide by baseline value. Baseline is geometric mean of Visit 2 (last value during run-in) and Visit 3 (Randomization).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Full analysis set excluded participants without baseline or post-baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1236</title>
            <description>AZD1236 75mg oral tablet twice daily(bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to AZD1236 twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of TNF Alpha at Week 6 to Baseline</title>
          <description>Ratio reflects Sputum Tumor Necrosis Factor alpha (TNF alpha) at week 6 value divide by baseline value. Baseline is geometric mean of Visit 2 (last value during run-in) and Visit 3 (Randomization).</description>
          <population>Full analysis set excluded participants without baseline or post-baseline data.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" spread="0.532" lower_limit="0.532" upper_limit="18.7"/>
                    <measurement group_id="O2" value="1.21" spread="0.270" lower_limit="0.270" upper_limit="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ratio of Sputum Total Cells at Week 6 to Baseline</title>
        <description>Ratio reflects Sputum Total Cells at week 6 value divide by baseline value. Baseline is geometric mean of Visit 2 (last value during run-in) and Visit 3 (Randomization).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Full analysis set excluded participants without baseline or post-baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1236</title>
            <description>AZD1236 75mg oral tablet twice daily(bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to AZD1236 twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Sputum Total Cells at Week 6 to Baseline</title>
          <description>Ratio reflects Sputum Total Cells at week 6 value divide by baseline value. Baseline is geometric mean of Visit 2 (last value during run-in) and Visit 3 (Randomization).</description>
          <population>Full analysis set excluded participants without baseline or post-baseline data.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="0.209" lower_limit="0.209" upper_limit="4.03"/>
                    <measurement group_id="O2" value="0.876" spread="0.002" lower_limit="0.002" upper_limit="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ratio of Total Urine Desmosine at Week 6 to Baseline</title>
        <description>Ratio reflects Total Urine Desmosine at week 6 value divide by baseline value. Baseline is visit 3(Randomization) value.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Full analysis set excluded participants without baseline or post-baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1236</title>
            <description>AZD1236 75mg oral tablet twice daily(bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to AZD1236 twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Total Urine Desmosine at Week 6 to Baseline</title>
          <description>Ratio reflects Total Urine Desmosine at week 6 value divide by baseline value. Baseline is visit 3(Randomization) value.</description>
          <population>Full analysis set excluded participants without baseline or post-baseline data.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.946" spread="0.240" lower_limit="0.240" upper_limit="5.44"/>
                    <measurement group_id="O2" value="1.27" spread="0.387" lower_limit="0.387" upper_limit="5.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events</title>
        <description>Number of patients who had an AE</description>
        <time_frame>all study visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD1236</title>
            <description>AZD1236 75mg oral tablet twice daily(bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to AZD1236 twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events</title>
          <description>Number of patients who had an AE</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Forced Expiratory Volume (FEV1) at Week 6</title>
        <description>Change from baseline reflects the Week 6 value minus the baseline value. Baseline is visit 3(randomization) value.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Full analysis set completed at week 6</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1236</title>
            <description>AZD1236 75mg oral tablet twice daily(bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to AZD1236 twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Expiratory Volume (FEV1) at Week 6</title>
          <description>Change from baseline reflects the Week 6 value minus the baseline value. Baseline is visit 3(randomization) value.</description>
          <population>Full analysis set completed at week 6</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.025" spread="-0.510" lower_limit="-0.510" upper_limit="0.670"/>
                    <measurement group_id="O2" value="-0.063" spread="-0.670" lower_limit="-0.670" upper_limit="0.550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Forced Vital Capacity (FVC) at Week 6</title>
        <description>Change from baseline reflects the Week 6 value minus the baseline value. Baseline is visit 3(randomization) value.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Full analysis set completed at week 6</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1236</title>
            <description>AZD1236 75mg oral tablet twice daily(bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to AZD1236 twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Vital Capacity (FVC) at Week 6</title>
          <description>Change from baseline reflects the Week 6 value minus the baseline value. Baseline is visit 3(randomization) value.</description>
          <population>Full analysis set completed at week 6</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.103" spread="-0.960" lower_limit="-0.960" upper_limit="0.740"/>
                    <measurement group_id="O2" value="-0.104" spread="-0.900" lower_limit="-0.900" upper_limit="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital Capacity (VC) at Week 6</title>
        <description>Change from baseline reflects the Week 6 value minus the baseline value. Baseline is visit 3(randomization) value.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Full analysis set completed at week 6</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1236</title>
            <description>AZD1236 75mg oral tablet twice daily(bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to AZD1236 twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Capacity (VC) at Week 6</title>
          <description>Change from baseline reflects the Week 6 value minus the baseline value. Baseline is visit 3(randomization) value.</description>
          <population>Full analysis set completed at week 6</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.098" spread="-0.680" lower_limit="-0.680" upper_limit="2.72"/>
                    <measurement group_id="O2" value="-0.110" spread="-0.840" lower_limit="-0.840" upper_limit="0.590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Inspiratory Capacity (IC) at Week 6</title>
        <description>Change from baseline reflects the Week 6 value minus the baseline value. Baseline is visit 3(randomization) value.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Full analysis set completed at week 6</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1236</title>
            <description>AZD1236 75mg oral tablet twice daily(bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to AZD1236 twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Inspiratory Capacity (IC) at Week 6</title>
          <description>Change from baseline reflects the Week 6 value minus the baseline value. Baseline is visit 3(randomization) value.</description>
          <population>Full analysis set completed at week 6</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.082" spread="-0.700" lower_limit="-0.700" upper_limit="0.500"/>
                    <measurement group_id="O2" value="-0.173" spread="-2.19" lower_limit="-2.19" upper_limit="0.840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Forced Expiratory Flow (FEF) 25−75% at Week 6</title>
        <description>Change from baseline reflects the Week 6 value minus the baseline value. Baseline is visit 3(randomization) value.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Full analysis set completed at week 6</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1236</title>
            <description>AZD1236 75mg oral tablet twice daily(bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to AZD1236 twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Expiratory Flow (FEF) 25−75% at Week 6</title>
          <description>Change from baseline reflects the Week 6 value minus the baseline value. Baseline is visit 3(randomization) value.</description>
          <population>Full analysis set completed at week 6</population>
          <units>L/s</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.007" spread="-0.410" lower_limit="-0.410" upper_limit="0.260"/>
                    <measurement group_id="O2" value="-0.067" spread="-0.780" lower_limit="-0.780" upper_limit="0.230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Peak Expiratory Flow (PEF) Morning at Average of Last 4 Week Treatment</title>
        <description>Change from baseline reflects the average of last 4 week on treatment (Week 1, Week 2, Week 4 and Week 6) minus the baseline value. Baseline is the mean of the last 10 days of data during run-in.</description>
        <time_frame>Baseline and last 4 week on treatment(Week 1, Week 2, Week 4 and Week 6)</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1236</title>
            <description>AZD1236 75mg oral tablet twice daily(bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to AZD1236 twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Peak Expiratory Flow (PEF) Morning at Average of Last 4 Week Treatment</title>
          <description>Change from baseline reflects the average of last 4 week on treatment (Week 1, Week 2, Week 4 and Week 6) minus the baseline value. Baseline is the mean of the last 10 days of data during run-in.</description>
          <population>Full analysis set</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.81" spread="-61.2" lower_limit="-61.2" upper_limit="26.2"/>
                    <measurement group_id="O2" value="-7.73" spread="-73.2" lower_limit="-73.2" upper_limit="43.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Peak Expiratory Flow (PEF) Evening at Average of Last 4 Week Treatment</title>
        <description>Change from baseline reflects the average of last 4 week on treatment (Week 1, Week 2, Week 4 and Week 6) minus the baseline value. Baseline is the mean of the last 10 days of data during run-in.</description>
        <time_frame>Baseline and last 4 week on treatment(Week 1, Week 2, Week 4 and Week 6)</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1236</title>
            <description>AZD1236 75mg oral tablet twice daily(bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to AZD1236 twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Peak Expiratory Flow (PEF) Evening at Average of Last 4 Week Treatment</title>
          <description>Change from baseline reflects the average of last 4 week on treatment (Week 1, Week 2, Week 4 and Week 6) minus the baseline value. Baseline is the mean of the last 10 days of data during run-in.</description>
          <population>Full analysis set</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.6" spread="-80.3" lower_limit="-80.3" upper_limit="30.1"/>
                    <measurement group_id="O2" value="-13.5" spread="-102" lower_limit="-102" upper_limit="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinical COPD Questionnaire(CCQ) Total</title>
        <description>Change from baseline reflects the Week 6 value minus the baseline value. Baseline is visit 3(randomization) value. The total scores vary between 0 (never/not limited at all) to 6 (almost all the time/totally limited)</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1236</title>
            <description>AZD1236 75mg oral tablet twice daily(bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to AZD1236 twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical COPD Questionnaire(CCQ) Total</title>
          <description>Change from baseline reflects the Week 6 value minus the baseline value. Baseline is visit 3(randomization) value. The total scores vary between 0 (never/not limited at all) to 6 (almost all the time/totally limited)</description>
          <population>Full analysis set</population>
          <units>Score on scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.011" spread="-0.800" lower_limit="-0.800" upper_limit="1.40"/>
                    <measurement group_id="O2" value="-0.241" spread="-1.74" lower_limit="-1.74" upper_limit="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in COPD Symptoms, Breathlessness at Average of Last 4 Week Treatment</title>
        <description>Change from baseline reflects the average of last 4 week on treatment (Week 1, Week 2, Week 4 and Week 6) minus the baseline value. Baseline is the mean of the last 10 days of data during run-in. Score vary between 0 (None) to 4 (Severe).</description>
        <time_frame>Baseline and last 4 week on treatment(Week 1, Week 2, Week 4 and Week 6)</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1236</title>
            <description>AZD1236 75mg oral tablet twice daily(bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to AZD1236 twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in COPD Symptoms, Breathlessness at Average of Last 4 Week Treatment</title>
          <description>Change from baseline reflects the average of last 4 week on treatment (Week 1, Week 2, Week 4 and Week 6) minus the baseline value. Baseline is the mean of the last 10 days of data during run-in. Score vary between 0 (None) to 4 (Severe).</description>
          <population>Full analysis set</population>
          <units>Score on scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.191" spread="-1.51" lower_limit="-1.51" upper_limit="1.00"/>
                    <measurement group_id="O2" value="-0.338" spread="-1.74" lower_limit="-1.74" upper_limit="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in COPD Symptoms, Chest Tightness at Average of Last 4 Week Treatment</title>
        <description>Change from baseline reflects the average of last 4 week on treatment (Week 1, Week 2, Week 4 and Week 6) minus the baseline value. Baseline is the mean of the last 10 days of data during run-in. Score vary between 0 (None) to 4 (Severe).</description>
        <time_frame>Baseline and last 4 week on treatment(Week 1, Week 2, Week 4 and Week 6)</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1236</title>
            <description>AZD1236 75mg oral tablet twice daily(bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to AZD1236 twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in COPD Symptoms, Chest Tightness at Average of Last 4 Week Treatment</title>
          <description>Change from baseline reflects the average of last 4 week on treatment (Week 1, Week 2, Week 4 and Week 6) minus the baseline value. Baseline is the mean of the last 10 days of data during run-in. Score vary between 0 (None) to 4 (Severe).</description>
          <population>Full analysis set</population>
          <units>Score on scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.149" spread="-1.11" lower_limit="-1.11" upper_limit="1.00"/>
                    <measurement group_id="O2" value="-0.156" spread="-1.74" lower_limit="-1.74" upper_limit="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in COPD Symptoms, Cough Score at Average of Last 4 Week Treatment</title>
        <description>Change from baseline reflects the average of last 4 week on treatment (Week 1, Week 2, Week 4 and Week 6) minus the baseline value. Baseline is the mean of the last 10 days of data during run-in. Score vary between 0 (None) to 4 (Almost Constant).</description>
        <time_frame>Baseline and last 4 week on treatment(Week 1, Week 2, Week 4 and Week 6)</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1236</title>
            <description>AZD1236 75mg oral tablet twice daily(bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to AZD1236 twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in COPD Symptoms, Cough Score at Average of Last 4 Week Treatment</title>
          <description>Change from baseline reflects the average of last 4 week on treatment (Week 1, Week 2, Week 4 and Week 6) minus the baseline value. Baseline is the mean of the last 10 days of data during run-in. Score vary between 0 (None) to 4 (Almost Constant).</description>
          <population>Full analysis set</population>
          <units>Score on scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.114" spread="-1.81" lower_limit="-1.81" upper_limit="1.78"/>
                    <measurement group_id="O2" value="-0.324" spread="-1.94" lower_limit="-1.94" upper_limit="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in COPD Symptoms, Night Time Awakenings at Average of Last 4 Week Treatment</title>
        <description>Change from baseline reflects the average of last 4 week on treatment (Week 1, Week 2, Week 4 and Week 6) minus the baseline value. Baseline is the mean of the last 10 days of data during run-in. Score vary between 0 (None) to 4 (Almost Constant).</description>
        <time_frame>Baseline and last 4 week on treatment(Week 1, Week 2, Week 4 and Week 6)</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1236</title>
            <description>AZD1236 75mg oral tablet twice daily(bid)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to AZD1236 twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in COPD Symptoms, Night Time Awakenings at Average of Last 4 Week Treatment</title>
          <description>Change from baseline reflects the average of last 4 week on treatment (Week 1, Week 2, Week 4 and Week 6) minus the baseline value. Baseline is the mean of the last 10 days of data during run-in. Score vary between 0 (None) to 4 (Almost Constant).</description>
          <population>Full analysis set</population>
          <units>Score on scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.072" spread="-0.556" lower_limit="-0.556" upper_limit="1.38"/>
                    <measurement group_id="O2" value="-0.150" spread="-2.22" lower_limit="-2.22" upper_limit="0.976"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AZD1236</title>
          <description>AZD1236 75mg oral tablet twice daily(bid)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo to AZD1236 twice daily(bid)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Decompensation Cordis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Exacerbation COPD</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Increased Dyspnoe After Stopping Normal Treatment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

